Clinical Trial Update: Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of pemigatinib in high-risk urothelial cancer after radical surgery has been terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Cancer

Drugs mentioned

• Pemazyre (pemigatinib)

Snippet

Sponsor: European Association of Urology Research Foundation | Conditions: Urothelial Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-04-18